VivoSeq
Hematology

Macroglobulinemia

59

Pipeline Programs↗

19

Active Trials↗

28

Companies Involved↗

Macroglobulinemia is a moderately active landscape with 59 programs across 28 companies. The most active players are X4 Pharmaceuticals, Ascentage Pharma Group Inc., Novartis. 2 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

63/100

Pipeline Velocity

22/100

Mech. Concentration

10/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

X4 Pharmaceuticals

1 program

Phase 1Ascentage Pharma Group Inc. logo

Ascentage Pharma Group Inc.

1 program

Phase 1Novartis logo

Novartis

4 programs

Phase 2E

Eastern Cooperative Oncology Group

3 programs

Phase 2Eli Lilly logo

Eli Lilly

3 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

2 programs

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

81%

Small molecule

52 of 64 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody914%Protein / enzyme23%RNA therapy12%

Small molecule leads; the ring shows all 64 classified programs, each share of the total. Modality classified for 100% of 68 pipeline programs.

Analysis

Trial Status

86

clinical trials

Completed46 · 53%
Terminated13 · 15%
Recruiting8 · 9%
Active, not recruiting7 · 8%
Unknown status6 · 7%
Not yet recruiting4 · 5%
Other2 · 2%

Clinical Trials

Trial Activity

86 trials

A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Recruiting·BeiGene logoBeiGene·Phase 4·NCT07169331·18 enrolled
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia
Recruiting·KKosin University Gospel Hospital·Phase 2·NCT03697356·54 enrolled
Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia
Recruiting·—·N/A·NCT04893564·90 enrolled
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
Recruiting·—·Phase 2·NCT05099471·80 enrolled
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Recruiting·—·Phase 2·NCT05734495·42 enrolled
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Recruiting·BeiGene logoBeiGene·N/A·NCT05640102·111 enrolled
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Recruiting·—·Phase 2·NCT06986174·30 enrolled
Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia
Recruiting·—·N/A·NCT04898647·100 enrolled
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Active, not recruiting·BBeOne Medicines·Phase 2·NCT05952037·114 enrolled
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Active, not recruiting·AAcerta Pharma BV·Phase 2·NCT02180724·107 enrolled
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
Active, not recruiting·SSunnybrook Health Sciences Centre·Phase 2·NCT04624906·63 enrolled
Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
Active, not recruiting·—·Phase 2·NCT04263480·99 enrolled
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
Active, not recruiting·—·Phase 2·NCT03620903·53 enrolled
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00492050·46 enrolled
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Active, not recruiting·FFondazione Italiana Linfomi - ETS·N/A·NCT06441214·212 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)